Shin Poong Pharmaceutical Co., Ltd. (CEO Ryu Jei-Man)’s malaria treatment Pyramax will enter Cambodia.

Shin Poong said on the 11^th June, Pyramax, a Artemisin combination therapy for uncomplicated malaria supplied 15,000 doses for adult in Cambodia..

Since Pyramax has been launched in April, it is the first procurement from public agency - United Nations Project Procurement Organization (UNOPS).

UNOPS is one of the fund-operating agencies of the global fund and will operate this supply

In Cambodia, about 80,000 patients are reported to be infected with malaria every year.

Mostly public procurement is funded through The Global Fund or PMI (President's Malaria Initiative)

Currently, Cambodia is in urgently in needs of new ACT treatments due to unstable supply and demand of the first guideline treatment in the country.

As listed on WHO's Model List of Essential Medicines in 2017, "The clinical efficacy of the Pyramax drug efficacy in Cambodia has been proven in clinical trials," said Shin Poong staff. “Chosen to be appropriate option by the Cambodian national malaria program and worldwide public agencies is evaluated encouraging for future public procurement.”